FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146804131> ?p ?o ?g. }

• W2146804131 endingPage "377" @default.
• W2146804131 startingPage "369" @default.
• W2146804131 abstract "PURPOSE Human plasma–derived plasmin has been developed for the treatment of thrombosed hemodialysis arteriovenous grafts and vascular occlusive diseases. To further investigate this drug in large animal models and derive preliminary dosing estimates, the authors compared plasmin's relative lytic potential in four species, including man. The goal was to find which species' whole blood clots best compared to human clots in terms of lysis with plasmin. The results from these studies will serve to guide species selection for large animal experimentation. MATERIALS AND METHODS Clotted blood from human, pig, sheep, and bovine subjects were treated with saline solution control, plasmin, or tissue plasminogen activator. Electron microscopy (EM) techniques were used to investigate the effects of clot size and fragmentation on plasmin lysis, the effects of intrathrombic infusion by injection of plasmin directly into whole blood clots, and species fibrin structural differences. RESULTS Under static conditions, plasmin efficiently lysed clots from all species studied at an optimal dose of 4–5 mg per 4–5 g of clot. With fragmented human clots, plasmin (5 mg)–induced lysis was 80% ± 2% at 60 minutes. Porcine clots were more resistant to plasmin lysis compared with human, ovine, and bovine clots. Percent lysis at 60 minutes with plasmin for ovine clots was 72% ± 3% (4-mg dose), compared with 50% ± 4% for porcine clots (5-mg dose; P < .05). EM of porcine clots showed a compact fibrin network that appeared more dense than that in human or sheep clots, which may account for the decreased lytic rate. CONCLUSION Human plasmin is an effective direct-acting thrombolytic agent that is capable of lysing fibrin from several species. Ex vivo lysis studies were used to investigate the most appropriate large animal model that best approximates plasmin lysis with human clots under certain conditions. It was determined that ovine clots treated with plasmin most closely resemble the lysis observed with human clots. Human plasma–derived plasmin has been developed for the treatment of thrombosed hemodialysis arteriovenous grafts and vascular occlusive diseases. To further investigate this drug in large animal models and derive preliminary dosing estimates, the authors compared plasmin's relative lytic potential in four species, including man. The goal was to find which species' whole blood clots best compared to human clots in terms of lysis with plasmin. The results from these studies will serve to guide species selection for large animal experimentation. Clotted blood from human, pig, sheep, and bovine subjects were treated with saline solution control, plasmin, or tissue plasminogen activator. Electron microscopy (EM) techniques were used to investigate the effects of clot size and fragmentation on plasmin lysis, the effects of intrathrombic infusion by injection of plasmin directly into whole blood clots, and species fibrin structural differences. Under static conditions, plasmin efficiently lysed clots from all species studied at an optimal dose of 4–5 mg per 4–5 g of clot. With fragmented human clots, plasmin (5 mg)–induced lysis was 80% ± 2% at 60 minutes. Porcine clots were more resistant to plasmin lysis compared with human, ovine, and bovine clots. Percent lysis at 60 minutes with plasmin for ovine clots was 72% ± 3% (4-mg dose), compared with 50% ± 4% for porcine clots (5-mg dose; P < .05). EM of porcine clots showed a compact fibrin network that appeared more dense than that in human or sheep clots, which may account for the decreased lytic rate. Human plasmin is an effective direct-acting thrombolytic agent that is capable of lysing fibrin from several species. Ex vivo lysis studies were used to investigate the most appropriate large animal model that best approximates plasmin lysis with human clots under certain conditions. It was determined that ovine clots treated with plasmin most closely resemble the lysis observed with human clots." @default.
• W2146804131 created "2016-06-24" @default.
• W2146804131 creator A5025951411 @default.
• W2146804131 creator A5036886965 @default.
• W2146804131 creator A5056040531 @default.
• W2146804131 date "2005-03-01" @default.
• W2146804131 modified "2023-10-14" @default.
• W2146804131 title "Cross-Species Pharmacologic Evaluation of Plasmin as a Direct-Acting Thrombolytic Agent: Ex Vivo Evaluation for Large Animal Model Development" @default.
• W2146804131 cites W1514531933 @default.
• W2146804131 cites W1846063887 @default.
• W2146804131 cites W1969537125 @default.
• W2146804131 cites W1971917522 @default.
• W2146804131 cites W1977221060 @default.
• W2146804131 cites W1977497608 @default.
• W2146804131 cites W1978579910 @default.
• W2146804131 cites W1988033812 @default.
• W2146804131 cites W2000502450 @default.
• W2146804131 cites W2019241819 @default.
• W2146804131 cites W2023791412 @default.
• W2146804131 cites W2050800630 @default.
• W2146804131 cites W2060626892 @default.
• W2146804131 cites W2062304091 @default.
• W2146804131 cites W2065349081 @default.
• W2146804131 cites W2080530368 @default.
• W2146804131 cites W2087299903 @default.
• W2146804131 cites W2091047419 @default.
• W2146804131 cites W2120398848 @default.
• W2146804131 cites W2162194914 @default.
• W2146804131 cites W2191994209 @default.
• W2146804131 cites W2303694787 @default.
• W2146804131 cites W2410442987 @default.
• W2146804131 cites W4322696917 @default.
• W2146804131 cites W74915632 @default.
• W2146804131 doi "https://doi.org/10.1097/01.rvi.0000148828.40438.d3" @default.
• W2146804131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15758133" @default.
• W2146804131 hasPublicationYear "2005" @default.
• W2146804131 type Work @default.
• W2146804131 sameAs 2146804131 @default.
• W2146804131 citedByCount "16" @default.
• W2146804131 countsByYear W21468041312012 @default.
• W2146804131 countsByYear W21468041312015 @default.
• W2146804131 countsByYear W21468041312016 @default.
• W2146804131 countsByYear W21468041312017 @default.
• W2146804131 countsByYear W21468041312018 @default.
• W2146804131 countsByYear W21468041312020 @default.
• W2146804131 countsByYear W21468041312021 @default.
• W2146804131 countsByYear W21468041312022 @default.
• W2146804131 crossrefType "journal-article" @default.
• W2146804131 hasAuthorship W2146804131A5025951411 @default.
• W2146804131 hasAuthorship W2146804131A5036886965 @default.
• W2146804131 hasAuthorship W2146804131A5056040531 @default.
• W2146804131 hasConcept C126322002 @default.
• W2146804131 hasConcept C181199279 @default.
• W2146804131 hasConcept C182615771 @default.
• W2146804131 hasConcept C202751555 @default.
• W2146804131 hasConcept C203014093 @default.
• W2146804131 hasConcept C2522874641 @default.
• W2146804131 hasConcept C26291073 @default.
• W2146804131 hasConcept C2776336681 @default.
• W2146804131 hasConcept C2776572282 @default.
• W2146804131 hasConcept C2776825266 @default.
• W2146804131 hasConcept C2779581417 @default.
• W2146804131 hasConcept C2779679481 @default.
• W2146804131 hasConcept C2781071845 @default.
• W2146804131 hasConcept C500558357 @default.
• W2146804131 hasConcept C54173615 @default.
• W2146804131 hasConcept C55493867 @default.
• W2146804131 hasConcept C57409179 @default.
• W2146804131 hasConcept C71924100 @default.
• W2146804131 hasConcept C86803240 @default.
• W2146804131 hasConcept C98274493 @default.
• W2146804131 hasConceptScore W2146804131C126322002 @default.
• W2146804131 hasConceptScore W2146804131C181199279 @default.
• W2146804131 hasConceptScore W2146804131C182615771 @default.
• W2146804131 hasConceptScore W2146804131C202751555 @default.
• W2146804131 hasConceptScore W2146804131C203014093 @default.
• W2146804131 hasConceptScore W2146804131C2522874641 @default.
• W2146804131 hasConceptScore W2146804131C26291073 @default.
• W2146804131 hasConceptScore W2146804131C2776336681 @default.
• W2146804131 hasConceptScore W2146804131C2776572282 @default.
• W2146804131 hasConceptScore W2146804131C2776825266 @default.
• W2146804131 hasConceptScore W2146804131C2779581417 @default.
• W2146804131 hasConceptScore W2146804131C2779679481 @default.
• W2146804131 hasConceptScore W2146804131C2781071845 @default.
• W2146804131 hasConceptScore W2146804131C500558357 @default.
• W2146804131 hasConceptScore W2146804131C54173615 @default.
• W2146804131 hasConceptScore W2146804131C55493867 @default.
• W2146804131 hasConceptScore W2146804131C57409179 @default.
• W2146804131 hasConceptScore W2146804131C71924100 @default.
• W2146804131 hasConceptScore W2146804131C86803240 @default.
• W2146804131 hasConceptScore W2146804131C98274493 @default.
• W2146804131 hasIssue "3" @default.
• W2146804131 hasLocation W21468041311 @default.
• W2146804131 hasLocation W21468041312 @default.
• W2146804131 hasOpenAccess W2146804131 @default.
• W2146804131 hasPrimaryLocation W21468041311 @default.
• W2146804131 hasRelatedWork W1857113870 @default.
• W2146804131 hasRelatedWork W1986317812 @default.

• next